|
India News Releases
|
(India.CityRegions.Com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Hypertriglyceridemia - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market. Summary Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hypertriglyceridemia-pipeline-review-h2-2016 Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530744/sample
Few Points from Table of Content: List of Tables 6 List of Figures 7 Introduction 8 Publisher Report Coverage 8 Hypertriglyceridemia Overview 9 Therapeutics Development 10 Pipeline Products for Hypertriglyceridemia - Overview 10 Pipeline Products for Hypertriglyceridemia - Comparative Analysis 11 Hypertriglyceridemia - Therapeutics under Development by Companies 12 Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes 14 Hypertriglyceridemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Hypertriglyceridemia - Products under Development by Companies 18 Hypertriglyceridemia - Products under Investigation by Universities/Institutes 19 Hypertriglyceridemia - Companies Involved in Therapeutics Development 20 Acasti Pharma Inc 20 Akcea Therapeutics Inc 21 Allergan Plc 22 Alnylam Pharmaceuticals Inc 23 Arisaph Pharmaceuticals Inc 24 AstraZeneca Plc 25 BASF SE 26 Cardax Inc 27 Catabasis Pharmaceuticals Inc 28 Celon Pharma SA 29 CymaBay Therapeutics Inc 30 Gemphire Therapeutics Inc 31 Jeil Pharmaceutical Co Ltd 32 Kyorin Pharmaceutical Co Ltd 33 LipimetiX Development Inc 34 Matinas BioPharma Holdings Inc 35 Sancilio & Company Inc 36 Zydus Cadila Healthcare Ltd 37 Hypertriglyceridemia - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 AEM-28 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AEM-2814 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ALN-AC3 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 ALN-ANG - Drug Profile 51
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|